Overview of Coristina D

Quick Facts

Property	Description
Active Ingredients	Acetylsalicylic Acid, Caffeine, Dexchlorpheniramine Maleate, Phenylephrine Hydrochloride
Form	Oral solid preparation (Tablet)
Pharmacological Class	Compound Analgesic, H1-Antihistamine, and Sympathomimetic combination
General Purpose	Multi-symptom relief for cold, flu, and allergy symptoms
Origin	Synthetic chemical entities

Coristina D: Identity and Pharmacological Classification

Coristina D is an oral solid preparation, formulated as a distinctive fixed-dose combination product designed for systemic administration. This preparation is classified pharmacologically as a blend that effectively combines the actions of an Analgesic-Antipyretic, an H1-Antihistamine, and a Sympathomimetic agent. The medication consists of synthetic chemical entities that work collectively to provide broad symptomatic relief.

The Four-Component Composition and Differentiation

The product's profile is defined by its four distinct active ingredients: Acetylsalicylic Acid (Aspirin), Caffeine, Dexchlorpheniramine Maleate, and Phenylephrine Hydrochloride. This specific quadruple-component inclusion provides differentiation from simpler cold preparations that may contain fewer active agents. Acetylsalicylic Acid targets pain and fever, while Dexchlorpheniramine Maleate reduces allergic manifestations. The sympathomimetic component, Phenylephrine, is included to address nasal obstruction to improve breathing. The inclusion of Caffeine is intended to offset the sedation that can be caused by the antihistamine component, offering a coordinated therapeutic effect.

General Purpose: Comprehensive Symptomatic Relief

The primary purpose of Coristina D is to deliver comprehensive multi-symptom relief by addressing the most common co-occurring physical manifestations of colds, influenza, and specific allergies. This compound formulation provides support against general malaise, fever, pain, allergic responses, and upper respiratory congestion simultaneously. This multi-component product is intended for the discomforts of the common cold. Its role is strictly focused on symptomatic management, utilizing its multi-component action to alleviate distress and restore comfort.

Regulatory References

NIH Drug Profile

What side effects are possible with Coristina D?

Possible side effects and safety information

The official safety profile for this four-component medication is based on the combined regulatory documentation for its active ingredients. Adverse reactions are classified by frequency and the body system affected, providing a structured overview of potential effects.

Adverse Reaction Scope

The most frequently classified reactions, documented as Common in regulatory materials, relate to the nervous system and anticholinergic effects. These include drowsiness, dizziness, headache, dry mouth, dry nose, constipation, and blurred vision. Due to the presence of sympathomimetics and caffeine, effects such as nervousness, restlessness, and insomnia are also listed as common.

System-Organ Class (SOC)	Examples of Officially Listed Effects
Gastrointestinal Disorders	Nausea, vomiting, dyspepsia, heartburn, dry mouth, and constipation.
Nervous System Disorders	Sedation, dizziness, confusion, tremor, and headache.
Cardiac and Vascular Disorders	Palpitations, tachycardia, hypertension, and arrhythmias.

Serious Safety Considerations

Regulatory documentation highlights serious adverse reactions that are potentially life-threatening. The Acetylsalicylic Acid component carries a documented risk of serious gastrointestinal bleeding, ulceration, and perforation, a risk generally increasing with longer duration of use. Furthermore, the official label includes warnings about the possibility of severe allergic reactions and cardiovascular events such as severe hypertension.

Age-Specific Constraints are defined: the use of Acetylsalicylic Acid is explicitly contraindicated in children and teenagers who have a fever or viral illness due to the documented risk of Reye's syndrome.

Safety-Related Restrictions

Official labeling mandates that the medication is contraindicated for individuals with certain pre-existing conditions, including severe coronary artery disease, severe high blood pressure, narrow-angle glaucoma, severe liver damage, and bleeding disorders. The medication must also not be used within 14 days of taking a Monoamine Oxidase Inhibitor (MAOI) due to the risk of dangerous drug interactions.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory sources document that an overdose of this multi-component preparation results in a complex, multi-system toxicity profile, leading to potentially life-threatening physiological outcomes. The overdose manifestations combine the effects of all active ingredients, impacting the Central Nervous System (CNS), cardiovascular, and metabolic systems.

Documented Manifestations and Severe Outcomes

Presentations may include signs of salicylate toxicity such as tinnitus, profuse sweating, and severe metabolic acidosis—a critical acid-base disturbance. Due to the combination of active agents, CNS effects may range from excitation, tremors, and hallucinations to profound drowsiness, seizures, and coma. Cardiovascular risks listed in official labeling include acute hypertension and severe ventricular arrhythmias. Gastrointestinal hemorrhage is also a documented concern.

Mandated Emergency Action

Regulatory authorities strictly mandate that immediate medical attention must be sought for any suspected overdose or accidental exposure. This urgent action is required even if the patient feels well, due to the potential for severe, delayed complications. The treatment procedures described in official documents are symptomatic and supportive, aiming to correct specific toxicities; this may involve administering sodium bicarbonate to manage acidosis or using alpha-adrenergic blockers to control hypertensive crises.

Population-Specific Considerations

Official labeling notes special vulnerability in certain groups, including children (increased risk of CNS effects) and the elderly (increased susceptibility to gastrointestinal bleeding).

Therapeutic Uses of Coristina D

What Coristina D Treats: Main Uses and Benefits

Coristina D is commonly used for managing symptoms associated with acute or episodic changes that may intensify temporarily. The medication is applied across therapeutic domains where short-term symptomatic assistance is appropriate.

Symptomatic Relief and Therapeutic Scope

This compound is relevant for easing symptom clusters that may become intense or disruptive. It is used for managing symptoms related to systemic imbalance and irritative states, including manifestations of the common cold, influenza (flu), and allergic rhinitis. The medication contributes to improved comfort during periods of heightened symptoms, which assists with maintaining functional stability.

“It provides supportive relief when multiple symptoms occur together.”

Quick Fact: Relief for Multiple Discomforts

Area of Relief	Symptoms Managed
Systemic	Headache, body pain, elevated body temperature (fever)
Nasal/Secretory	Nasal obstruction, runny nose, sneezing
Context	Acute episodes of cold, flu, and seasonal allergies

Regulatory References

NIH MedlinePlus overview of Phenylephrine

Eligibility and Restrictions for Use

Eligibility and Restrictions for Coristina D

Coristina D is generally intended for adults and adolescents aged 12 years and over. However, official regulatory documents define strict criteria for its use, primarily based on contraindications related to its active ingredients (Acetylsalicylic Acid, Phenylephrine, Dexchlorpheniramine).

Absolute Contraindications

Use is strictly prohibited for patients with severe uncontrolled hypertension, severe coronary artery disease, or active gastrointestinal ulceration/bleeding disorders. It is also contraindicated for individuals taking Monoamine Oxidase Inhibitors (MAOIs).

Age and Physiological Status

The medicine is contraindicated for children under 12 years. Use is prohibited during the third trimester of pregnancy and is not recommended while breastfeeding. Older adults and patients with severe hepatic or renal impairment are designated populations for whom use requires special caution or is restricted.

Comorbidity Limitations

Restrictions also apply to patients with conditions like narrow-angle glaucoma, prostatic hypertrophy, and a history of aspirin-exacerbated asthma; use in these populations is generally restricted or requires specific medical guidance as per the official label.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile of this medication is derived from the established regulatory documentation for its four active components.

Formal Restrictions and Timing Rules

The official labeling classifies Monoamine Oxidase Inhibitors (MAOIs) and other Sympathomimetic Agents as contraindicated combinations due to the risk of severe hypertensive reactions. A mandatory timing requirement is documented, prohibiting the use of this medication during or within 14 days following the discontinuation of MAOI therapy.

Documented Interaction Patterns

Interaction Type	Interacting Agents (Examples)	Official Outcome Description
Additive CNS Effects	CNS Depressants (e.g., Opioid Analgesics, Anxiolytics)	Results in additive CNS depressant effects (enhanced sedation).
Increased Bleeding Risk	Anticoagulants (e.g., Warfarin), SSRIs/SNRIs, Steroids	Documented increase in bleeding risk due to inhibition of metabolism of anticoagulants and antiplatelet effects.
Pressor Potentiation	Oxytocic Drugs, Tricyclic Antidepressants	Agents that can potentiate the pressor effect of the decongestant component.

Alcohol is noted to increase the risk of both sedation and the Acetylsalicylic Acid-related stomach bleeding documented in the labeling. Official regulatory information also notes that the risk of severe bleeding is higher for Elderly Patients (age 60 or older) with concomitant use of hemostasis-interfering drugs.

Mechanism of Action

Coristina D: How The Quadruple Mechanism Works

Modulating Central and Peripheral Pain Mediators

This domain involves Acetylsalicylic Acid's (ASA) action as an irreversible inhibitor of the Cyclooxygenase (COX) enzymes. By blocking the synthesis of Prostaglandin E2 ( PGE2) in the central thermoregulatory center and at peripheral nerve endings, the mechanism stabilizes the hypothalamic temperature set-point and reduces the intensity of nociceptive signaling.

Coordinated Control of Vascular Permeability and Tone

The decongestant mechanism operates on two complementary pathways. Phenylephrine acts as an agonist on alpha1-Adrenergic receptors to constrict local blood vessels , while Dexchlorpheniramine acts as a competitive antagonist on Histamine H1 receptors to prevent histamine-induced fluid leakage from capillaries. This coordinated control of vascular tone and permeability results in decreased local tissue perfusion and fluid volume.

Pathway Balance via Adenosine Receptor Antagonism

The mechanism of Caffeine involves the non-selective antagonism of Adenosine A1 and A 2A receptors. This action enhances neuronal excitability, which serves a dual mechanistic purpose: it enhances the anti-nociceptive action of ASA by modulating central pain pathways, and it modulates the central depressant activity resulting from H1 receptor blockade.

Dosage and Administration Information

How Coristina D is Used

Coristina D is administered strictly via the oral route, consistent with its formulation as an oral solid preparation (tablet) for systemic delivery. This medication follows an intermittent, as-needed usage pattern, meaning it is taken only when symptoms are active, not as continuous therapy. Use is governed by specific dosing intervals and maximum daily limits.

Standard Dosing and Frequency

Population	Standard Single Dose	Frequency Pattern	Maximum Daily Limit
Adults and Children ≥ 12 Years	1 tablet	Every 4 hours (as needed)	Not to exceed 6 tablets in 24 hours
Children 6 to 12 Years	1/2 tablet	Every 4 hours (as needed)	Not to exceed 3 tablets in 24 hours

These instructions establish a minimum four-hour interval between doses, which must be respected before the next tablet is taken. The medication is used for a short-term duration, dictated by the persistence of the temporary symptoms it is intended to manage.

Administration Requirements

The tablet must be swallowed whole and intact, consistent with standard oral administration procedures. Ingestion should occur with a sufficient quantity of water. Use in children under six years of age is not recommended without prior consultation. Adherence to the stated maximum daily dose is required for procedural compliance.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Coristina D

Evidence for Use in Common Cold and Influenza (Flu) Symptoms

The evidence for this combination therapy was evaluated in short-term Randomized Controlled Trials (RCTs) and systematic reviews that focused on combination products containing these types of components. Research was conducted to examine the multi-symptom approach for conditions characterized by fluctuating or episodic manifestations, such as the common cold or flu-like illness. Studies were conducted during periods of increased symptom activity and used in research exploring how symptoms change over time, focusing on outcomes related to physical discomfort and systemic or functional imbalance.

In these studies, researchers monitored patient-reported outcomes describing perceived discomfort, including overall symptom intensity scores and measures for specific symptoms like headache, body pain, fever, and nasal issues. Studies also monitored outcomes reflecting daily functioning or activity level, such as patient-reported measures on maintaining normal activities and patient-reported sleep quality. This evidence contributes to understanding symptom patterns over defined, short time intervals.

Evidence for Use in Allergic Manifestations

This part will describe the research structure, including controlled studies, that have been used to evaluate the components of the drug, particularly the antihistamine and decongestant, in research exploring outcomes related to conditions characterized by allergic manifestations.

Findings describe patterns observed in the studies regarding patient-assessed change in sneezing and nasal discharge, outcomes capturing phases of heightened symptom activity. The components were studied for episodic symptoms like sneezing and runny nose, primarily through controlled trials where the antihistamine and decongestant components were evaluated.

Areas of Scientific Uncertainty and Research Gaps

A key area of uncertainty relates to the oral Phenylephrine component included for nasal congestion. Regulatory authorities have published findings describing uncertainty about the performance of this component as an oral decongestant at the standard over-the-counter dosage.

Furthermore, comparative evidence is lacking for the precise four-component fixed-dose combination, meaning that systematic reviews often must rely on extrapolation of findings from similar products or studies of the individual components. Evidence quality varies across studies, and there is a recognized limitation that trial designs and outcome measures show significant variability, which limits the ability to draw direct comparisons.

Key Studies & References Phenylephrine Oral: MedlinePlus Drug Information (NIH Source)

Frequently Asked Questions (FAQ)

Common questions about Coristina D (FAQ)

Q: How quickly does Coristina D start working after I take it?

A: According to official product information, the estimated time for the medication to begin working is approximately 30 minutes after the tablet is taken. This estimated onset time is based on the general absorption profile of the active ingredients.

Q: Does Coristina D interact with common medications like ibuprofen or Tylenol?

A: Official warnings note that the Acetylsalicylic Acid (ASA) component is known to interact with certain pain relievers. Taking this medicine with other non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen may increase the risk of bleeding. Taking it alongside products containing Acetaminophen (Tylenol) may increase the risk of side effects from that component. The full spectrum of specific warnings regarding interactions with other medicines is detailed in the official product labeling.

Q: Are there any long-term side effects associated with Coristina D use?

A: Cold and flu medicines like this one are generally intended for short-term use, and official labeling reflects this. The Acetylsalicylic Acid (ASA) component is associated with a risk of serious gastrointestinal bleeding, ulceration, and perforation. Official information indicates this risk may increase if the medication is used for longer durations than recommended.

Q: Can Coristina D make my heart race or feel irregular?

A: Yes, official safety information indicates that common side effects related to the decongestant and caffeine components include palpitations, which is a feeling of a racing or irregular heartbeat, as well as general nervousness. These are known effects of sympathomimetics and stimulants.

Q: Why do some people say Coristina D gives them a jittery feeling?

A: The 'jittery feeling' is a common expression for the side effects of nervousness and restlessness. These effects are associated with the stimulant properties of the Phenylephrine (decongestant) and Caffeine components included in the formulation.

Q: What is the maximum amount of time I should use Coristina D?

A: This medication is intended for short-term symptomatic relief of temporary cold and flu symptoms. General regulatory guidance for over-the-counter cold medicines typically advises limiting use to a short-term duration, often not exceeding seven days, or discontinuing use if symptoms do not begin to improve.

Q: What are the signs of an allergic reaction to Coristina D?

A: Official safety information regarding severe allergic reactions instructs users to discontinue the product and seek immediate medical help if symptoms such as hives, difficulty breathing or wheezing, or swelling of the face, tongue, or throat are experienced.

Q: Is Coristina D an antibiotic or a pain reliever?

A: Coristina D is not classified as an antibiotic. It is a multi-component product that provides symptomatic relief, which includes its analgesic-antipyretic (pain reliever and fever reducer) action, along with decongestant and antihistamine effects.

Q: Is it safe to take Coristina D with alcohol?

A: Official warnings strongly advise against the consumption of alcoholic drinks while this medication is being used. Alcohol can increase the risk of stomach bleeding associated with the Acetylsalicylic Acid component and may enhance the sedative effects caused by the antihistamine component.

Q: Is Coristina D suitable for children, and what are the age guidelines?

A: The medication is generally indicated for adults and adolescents aged 12 years and over. It is strictly contraindicated for children under 12 years and for any child or teenager exhibiting symptoms of flu or chickenpox, due to the documented risk of Reye's syndrome associated with the Acetylsalicylic Acid component.

Q: What should I do if I miss a dose of Coristina D?

A: Since this is an as-needed medication for temporary symptoms, you may not be on a fixed schedule. If a dose is missed, it can be taken as soon as it is remembered, unless it is already almost time for the next scheduled dose. The medication is intended to be taken only as needed; therefore, taking two doses at the same time to compensate for a missed dose is not recommended.

Q: What happens if you take Coristina D on an empty stomach?

A: The Acetylsalicylic Acid component is known to potentially cause stomach irritation. While official administration instructions focus on swallowing the tablet whole with water, taking it with food is a common practice that may help to reduce the risk of stomach upset.

Q: Does Coristina D help with both a stuffy nose and a runny nose?

A: Yes, official indications confirm the product is formulated to help with multiple symptoms of the common cold. It is indicated for relief of nasal congestion (stuffy nose) due to the decongestant and for reducing runny nose and sneezing due to the antihistamine component.

Q: What foods or supplements should be avoided while taking Coristina D?

A: Official warnings strongly advise against the consumption of alcohol while this medicine is being used. Additionally, it is advised to limit or avoid foods, beverages (like coffee or energy drinks), and supplements that contain high amounts of caffeine, as excess caffeine can increase side effects such as nervousness and difficulty sleeping.

Q: What specific type of cough does Coristina D help to relieve?

A: The official product labeling does not list cough relief as an indication, as the formulation does not include a dedicated cough suppressant or expectorant.

Q: Are there different strengths or formulations of Coristina D?

A: Regulatory product information typically reflects a standard, single formulation for a fixed-dose combination product like this. Any variations in strength or active ingredient mix would be marketed as distinct products.

Q: How does Coristina D affect the central nervous system?

A: The medication has a mixed impact on the central nervous system (CNS). The antihistamine component can cause CNS depression (drowsiness), while the caffeine and decongestant components are CNS stimulants (causing nervousness and insomnia). The specific balance of these effects can vary from person to person.

Q: Can Coristina D be taken for pain relief only, without other cold symptoms?

A: This product is officially marketed as a multi-symptom relief combination. If taken only for pain, the user will still be consuming the antihistamine, decongestant, and caffeine components, which are not necessary for isolated pain relief and may result in the user experiencing side effects from unnecessary components.

Q: Does Coristina D affect sleep patterns?

A: Yes, official safety information indicates that the medication can affect sleep patterns. Common side effects include both drowsiness, which impacts daytime function, and insomnia (difficulty sleeping) or restlessness, which can interrupt normal sleep.

Q: What color are the Coristina D pills/capsules?

A: The color of the final tablet is not a regulatory safety requirement and may vary between different manufacturers or geographical markets. However, product descriptions often list the colorants used in the inactive ingredients.

Q: Is it safe to take Coristina D with other multi-symptom cold remedies?

A: Official warnings state that this product should not be taken with any other medicine containing similar active ingredients, such as an antihistamine, decongestant, or Acetylsalicylic Acid (ASA). The reason for this warning is to prevent the accidental duplication of ingredients, which could increase the potential for serious side effects.

Q: Is there a non-drowsy version of Coristina D?

A: This specific formulation contains Dexchlorpheniramine, an antihistamine known to cause drowsiness. Non-drowsy versions of similar cold medicines would typically contain a different type of antihistamine or omit it entirely, and would be sold under a separate name.

Q: Are there any known issues with taking Coristina D and operating machinery?

A: Official warnings note that due to the potential for marked drowsiness and dizziness from the antihistamine component, activities requiring full alertness, such as driving or operating heavy machinery, should be undertaken with caution.

Q: How is Coristina D eliminated from the body?

A: Regulatory data on pharmacokinetics indicate that the active ingredients are generally metabolized by the liver and then eliminated from the body primarily through the kidneys (via urine). The time it takes for elimination varies depending on the specific component.

Q: Does Coristina D affect the results of any common medical tests?

A: Yes, official product information notes that the antihistamine component (Dexchlorpheniramine) may interfere with or cause false results on certain skin allergy tests. It is usually advised that the use of this medication be stopped several days before undergoing a skin allergy test.

Q: Why is the decongestant part of Coristina D sometimes separated from the rest?

A: This is related to ongoing scientific discussions by regulatory authorities, who have published findings describing uncertainty about the performance of the oral Phenylephrine component as a nasal decongestant at the standard over-the-counter dosage. This scientific review is separate from the formal safety and dosing instructions on the label.

Q: Is Coristina D a non-addictive medication?

A: The product is classified as a human over-the-counter (OTC) drug and is not subject to controlled substance regulations by federal agencies. This means it is not classified as a scheduled drug.

How should Coristina D be stored and disposed of?

Storage and Protection

Coristina D tablets must be stored safely to maintain their stability and prevent accidental exposure.

Temperature and Conditions: Store in a cool, dry place away from extreme heat, air, light, and moisture. Avoid humid areas, such as a bathroom medicine cabinet.
Container and Handling: Keep the medicine strictly in its original container until the point of use. There are no special in-use stability constraints documented after opening.
Child Protection: Always store this medicine out of reach and sight of children to guard against accidental ingestion.

Disposal Requirements

The most appropriate method for disposing of unused or expired Coristina D is a drug take-back program (e.g., mail-back envelopes or drop-off locations).

If a take-back option is not readily available, the medicine is typically not on the regulatory flush list and can be thrown in the household trash by following these steps:

Remove the drug from its original packaging and mix it with an unappealing, non-edible substance (e.g., used coffee grounds, dirt, or cat litter).
Place the mixture into a sealed bag or container to prevent leakage.
Before discarding the empty packaging, scratch out all personal identifying information to protect privacy.

Coristina D